Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management. Methods: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results. Results: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability. Conclusions: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries.
Background/Objectives: Anxiety is common in multiple sclerosis (MS), but screening relies on general instruments that may miss specific presentations. We described anxiety subtypes in people with MS in Argentina, estimated how many cases a general screen would miss, and explored correlates and pre-diagnostic psychiatric symptoms. Methods: Cross-sectional online survey (March–May 2026) of adults with self-reported MS using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A), GAD-7, Social Phobia Inventory, Obsessive-Compulsive Inventory-Revised, Patient Health Questionnaire panic module and Fear Questionnaire, plus questions on pre-onset symptoms. Results: Of 84 participants (76.2% women; 79.8% relapsing-remitting), 41.7% scored HADS-A ≥ 8. Social anxiety (26.2%) was the most frequent subtype, followed by generalized anxiety (21.4%), obsessive-compulsive symptoms (20.2%) and panic disorder (11.9%). Among HADS-A-negative participants, 14.3% (95% CI 7.1–26.7%) screened positive for at least one subtype. Female gender and relapsing-remitting MS were associated with higher general and generalized anxiety scores, younger age with social anxiety, and disability with agoraphobic avoidance. Overall, 71.4% reported anxiety-related symptoms before MS onset; of these, 38.3% had consulted a specialist and 20.0% had received a psychiatric diagnosis. Conclusions: Anxiety in MS is frequent and heterogeneous. General screening alone may miss subtype-specific cases, and psychiatric symptoms often precede the MS diagnosis.